Theraclion receives FDA clearance for Sonovein platform to treat venous reflux on November 4

Key Facts

The U.S. Food and Drug Administration on November 4, 2026, granted Theraclion’s Sonovein platform marketing authorization through the De Novo pathway, according to a company statement published via Business Wire. The authorization covers the coagulation of blood vessels in patients with superficial venous reflux in segments of the great saphenous vein, a specific treatment scope that does not include varicose veins generally. The company said the decision opens the platform’s commercial implementation phase in the United States. The authorization is based on a pivotal study that showed a vein closure rate of 96.8% after 12 months. Theraclion is moving from regulatory review to building a U.S. treatment presence, beginning its rollout through reference centers and physician training.

Sonovein works externally, using high-intensity focused ultrasound to target the vein without a surgical incision or insertion of an intravascular catheter, according to Theraclion’s statement. This approach differs from procedures that require direct access to the vein, while U.S. use remains limited to the indication authorized by the FDA. The company said the authorization came through the De Novo pathway, which granted the device marketing authorization for the specified use. These limits are relevant to understanding the commercial decision, as they allow the company to begin in the U.S. market within a specific patient group and certain vein segments. The statement did not give a specific launch date.

The decision was based on the pivotal VEINRESET study, which included 70 patients at four U.S. and European centers, according to the company. The great saphenous vein closure rate was 96.8% after 12 months, the primary endpoint that Theraclion said the study met. In September 2025, the company had reported the same result, with a 95% confidence interval ranging from 88.3% to 99.2%. The 12-month follow-up also showed that 98.5% of participants had no venous reflux, according to the study results published at the time. Principal investigator Steve Elias said the results make focused ultrasound treatment “a reliable and viable option, equivalent to traditional therapies with additional benefits for patients.”

On safety, Theraclion reported no serious or unexpected adverse events during the study, with one mild adverse event recorded. These results form part of the clinical evidence the company presented in support of the platform’s use, alongside meeting the vein closure endpoint after 12 months. The authorization’s specific scope does not change the nature of the data on which it was based, but ties the approval to treatment of patients with superficial venous reflux in segments of the great saphenous vein. The company said its initial plan is to establish reference treatment centers through physician training, clinical qualification, and technical and service support. It did not specify when these steps would begin or a timeline for expanding them.

Theraclion says Sonovein has been used in more than 4,000 procedures and adopted by more than twenty facilities worldwide as of November 5, 2026. This prior use gives the company a stated operational base as it enters the U.S. market, where it intends to focus first on establishing reference centers. Chief Executive Martin Deterre said, “Our priority is to establish successful treatment centers, build sustainable adoption and achieve growth.” The company’s U.S. subsidiary is Sonovein Inc., according to the statement, while the commercial expansion path it described depends on physician training, clinical qualification, and support for the centers. The statement provided no figures for expected revenue or a launch date.

Market preparation also involves procedural coverage: the company said the Category III CPT code designated for noninvasive venous HIFU procedures became effective in the United States on October 1, 2026. According to Theraclion, the code enables standardized reporting and tracking of procedures, and the company described it as a first step toward coverage and reimbursement pathways. The statement did not announce that coverage or reimbursement had been finalized, nor did it specify a date for that. Alongside FDA authorization, the code represents another element of the commercial implementation phase the company is beginning, as its stated plan turns to building reference centers and qualifying medical teams. The statement did not specify when the U.S. launch would begin.